Novacyt acquires Southern Cross Diagnostics

Novacyt SA, a global player in molecular diagnostics, has signed an agreement to acquire Southern Cross Diagnostics (SCD), an Australian distributor of diagnostic products. The transaction, carried out by its subsidiary Novacyt Holdings UK Limited, is valued at AU$8.5 million, or approximately €5.1 million. Based in Sydney, SCD has been collaborating with Novacyt since the acquisition of Elucigene Diagnostics in 2019.

The acquisition of SCD gives Novacyt direct access to a growing Australian market. SCD, which generated £6.7 million in revenue in 2025, offers immediate growth opportunities for Novacyt. The transaction includes a contingent payment linked to SCD's future performance.

This acquisition strengthens Novacyt's growth strategy, particularly in the Asia-Pacific region. The company will continue to benefit from SCD's current leadership, provided by Nick Thliveris.